Key points from article :
Genesis Therapeutics, a biotech company specializing in AI-driven drug discovery, has raised $52 million in Series A funding to advance its innovative simulation technology. The company’s AI platform models molecules in a more complex and realistic way, representing them as 3D graphs rather than traditional chemical diagrams. This approach allows for more accurate predictions of a molecule’s properties, such as binding affinity and solubility, which are crucial in drug development.
Founded in 2019 by Evan Feinberg, Genesis aims to bridge deep neural network techniques with biophysical simulations, setting it apart from competitors. The company has already secured partnerships with major pharmaceutical firms like Genentech and is developing its own internal drug pipeline. The funding will support the hiring of AI researchers, software engineers, and medicinal chemists, as well as the establishment of in-house research labs.
Feinberg sees recent advances in protein structure prediction, such as AlphaFold’s breakthrough, as complementary to Genesis’ work. By combining AI-driven molecular modelling with real-world drug development expertise, the company hopes to accelerate the discovery of novel treatments for various diseases.
